Genta Genasense "Not Approvable"; Firm Blames Composite Endpoint
This article was originally published in The Pink Sheet Daily
Executive Summary
CEO Warrell tells "The Pink Sheet" DAILY that progression-free survival has no clinical value in the chronic lymphocytic leukemia setting.